Rare cancer share of oncology trial starts

Most oncology trials are focused on rare cancers, with 74% of trial starts in 2024 evaluating medicines for rare cancers, growing by 3% compared to 2023.

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

IQVIA Institute. (2024). Global Oncology Trends 2025. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Via StatOrigin, https://statorigin.org/stat/stat_CKTWGAVX6ERJR46BZNNYVM2FPH

Copy

MLA

IQVIA Institute. "Global Oncology Trends 2025." 2024, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed 16 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_CKTWGAVX6ERJR46BZNNYVM2FPH.

Copy

Chicago

IQVIA Institute. "Global Oncology Trends 2025." 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_CKTWGAVX6ERJR46BZNNYVM2FPH.

Copy

BibTeX

@misc{iqvia2024rarevm2fph, author = {{IQVIA Institute}}, title = {Global Oncology Trends 2025}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_CKTWGAVX6ERJR46BZNNYVM2FPH}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2025. Accessed September 16, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_CKTWGAVX6ERJR46BZNNYVM2FPH.